Private equity firms including Archimed, Cinven, and Gemspring are increasingly targeting the orthopedics sector, drawn to medical device production by lower development risks compared to pharmaceuticals. Value-based care trends and the sector's resiliency during economic downturns have made orthopedics a particularly attractive investment category for private equity players seeking stable returns.

The medical device subsector benefits from predictable reimbursement models and shorter development timelines compared to drug development, creating attractive risk-adjusted returns for investors. This shift reflects a broader trend in healthcare investing as PE firms pivot toward less capital-intensive healthcare segments with clearer regulatory pathways.

Recent activity includes Apollo's $1.25 billion minority investment in a McKesson Corporation surgical products business, underscoring the sector's appeal. Such deals highlight how private capital is reshaping the orthopedics landscape, consolidating fragmented markets while providing growth capital to established players.